[Parvovirus B19 seroprevalence in a group of schizophrenic patients]. / Séroprévalence du Parvovirus B19 dans un groupe de patients schizophrènes.

BACKGROUND: Schizophrenia is a highly disabling chronic mental illness. It is considerded as a neurodeveloppemental illness resulting from the interaction of genetic and environmental factors. Growing evidence supports the major role of prenatal infections and inflammation in the genesis of schizophrenia. The hypothesis including viral infections has been the subject of several studies and the role of parvovirus B19 (PB19) in the onset of the disease has been suggested. However, there is, up till now, no seroepidemiological evidence of his involvement. OBJECTIVE: To determine the prevalence of parvovirus B19 (PB19) in schizophrenic patients and in control subjects and to examine clinical associations between viral prevalence, risk factors of infectious disease and clinical features. METHOD: We carried out a case-control seroepidemiological study in the Psychiatry department of Farhat-Hached general hospital of Sousse (Tunisia). We recruited108 schizophrenic patients and 108 healthy controls free from any psychotic disorder and matched for age and sex. We collected sociodemographic data, medical history, axis I comorbid disorders and infectious risk factors. We assessed patients for psychopathology and severity of illness using respectively the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms (SANS), the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impressions (CGI). For each study participant, blood sample was collected and levels of IgG and IgM anti-PB19 were measured using the ELISA technique. RESULTS: The prevalence of IgG antibodies to PB19 was significantly higher in schizophrenic patients than in controls (73.1% vs 60.2%; P=0.04). There were no statistical differences between the two groups regarding the prevalence of IgM antibodies to PB19. No association was found between viral prevalence and sociodemographic data, risk factors for infection or clinical characteristics. The presence of PB19 antibodies was associated with a lower score on the PANSS negative subscale (P=0.04). No other signficative association were found. CONCLUSIONS: In our study, prevalence of IgG antibodies to PB19 was significantly higher in schizophrenic patients than in controls. This finding supports the hypothesis of the involvement of PB19 in schizophrenia. Further studies including both virological and immunological aspects are needed to better clarify the etiopathogenic mechanisms of schizophrenia which would challenge the management of this disease.

[Prevalence and correlates of major depressive episodes in Sousse primary care setting: assessment with the Tunisian version of CIDI]. / Prévalence et facteurs associés des épisodes dépressifs majeurs : Evaluation par la version tunisienne du CIDI dans les structures de première ligne de Sousse.

BACKGROUND: Major depression is a mental disorder that is associated with high morbidity and significant mortality. It is common among primary care attenders. Few is known about major depression prevalence and associated factors, which would prevent general practitioners from diagnosing it in primary care centres and treating it adequately. AIM: To determine prevalence and correlates of major depressive episodes (MDE) in a representative sample of primary care attenders in the area of Sousse (Tunisia). METHODS: A random and representative sample of primary care attenders was obtained by a two-stage sampling procedure. First, 30 primary care centres (20 urban and 10 rural) were selected, with stratification according to residency location. Second, 1246 consenting participants were systematically recruited among those centres attenders. Participants were screened, by trained interviewers, with Tunisian version of « Composite International Diagnostic Interview ¼ CIDI.2.1. After data entry in ishell program, MDE diagnosis was obtained according to ICD-10 criteria. RESULTS: Mean age in our sample was 43.4 ± 17.62 years, with feminine (70.9 %) and urban (67.8 %) predominance. MDE was found in 26.4 % of participants. Associated factors were female gender, marital statute of widowed or divorced and rural residency. CONCLUSION: This study provided data about high prevalence of MDE in the area of Sousse primary care centres and its correlated factors.

[Cholinesterase inhibitors and depression in the elderly]. / Intérêt des anticholinestérasiques dans les dépressions du sujet âgé

BACKGROUND: Depression in the elderly is characterized by an atypical expression with delusion, major anxiety, behaviour disorders, somatic complains or cognitive impairment. These clinical aspects are suspected to be at the origin of the poor response to antidepressants observed in these cases. It is currently indicated to add sedative medicines to antidepressants, when a major anxiety is associated with depression, or an antipsychotic in the delusional forms of the depression. However, it is not consensually established that cholinesterase inhibitors can be helpful in depression with cognitive impairment. Cholinesterase inhibitors are efficient among patients with Alzheimer disease. They improve cognitive performances and slow down the degenerative process during the first years of treatment. Today, new findings on neurobiological mechanisms of depression involve a located degenerative process, with some similar anomalies in the brain in both depression and pre-Alzheimer states. New therapeutic trials have shown that cholinesterase inhibitors can be also efficient on depressed symptoms among patients with Alzheimer disease. These evidences support the hypothesis that the association of cholinesterase inhibitors to antidepressants can bring more benefits to depressed elderly patients. AIM: Through a review of the literature and a case report, we tried to specify whether cholinesterase inhibitors can be useful in the treatment of depression among the elderly. CASE REPORT: We report the case of a 68-year-old man who had presented, four years ago, a second episode of major depression with a cognitive impairment. Treated with an antidepressant (venlafaxine), the improvement was poor with major anxiety, slow thoughts, and an evidence of a persistent cognitive impairment. Despite normal cerebral scanning images, we decided to add a cholinesterase inhibitor (donepezil) to the same antidepressant. With this association, we rapidly obtained a total remission from depression with restitution of cognitive performances. This state is still maintained until today (four years after the last depressive episode) with no new mood relapses. Recent cerebral scanning images did not show any degenerative process. CONCLUSION: The association of cholinesterase inhibitors and an antidepressant seems a good alternative, when the response to antidepressant is partial in depression with cognitive impairment in the elderly. However, further therapeutic trials are still needed, to prove the usefulness of cholinesterase inhibitors among depressed elderly patients.

[Delirium and hallucinations in depression: cultural aspects]. / Délires et hallucinations dans la dépression, aspect culturel.

Study of depression in North-Africa and Sub-Saharan Africa has shown that, since the seventies, the clinical expression of depression is markedly different from that of depression in the West. Several authors have noted the rareness of guilt themes and the frequency of persecution themes and somatic complaints in depressed Africans, even those living in the West. More recent studies have shown an evolution in depressive symptoms in North-Africa with an increase in guilt and a decrease in persecution and somatic complaints. This shift in symptoms brings the expression of depression closer to that observed in the West. Our study addresses delusional depression: in 73 cases of delusional depression, delusions of guilt were present in 31% of cases, persecution in 48% and hallucinations in 31.5%. A comparison of the sub-groups consulting in 1991 and a second sub-group consulting in 1998 shows a marked increase in guilt (23.5 versus 39%).

[The contribution of brain imaging in acute psychotic disorders]. / Apport de l'imagerie cérébrale dans les troubles psychotiques aigus.

In recent years research on the neuronal substrate for mental disorders has considerably developed thanks to new brain imaging methods. Functional brain imaging has attracted several workers in their investigations of psychiatric diseases. Some authors have addressed the position of imaging in the diagnosis and, above all, prognosis of acute psychotic disorders. In the following paper, the authors review the published results. Both structural and functional imaging confirm the hypothesis of a neurophysiological contribution to acute psychotic disorders, as shown by ventricular dilatation and functional abnormalities. Nonetheless, imaging does not seem to have a precise and absolute diagnostic and prognostic value, although of undeniable heuristic interest.

[Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal]. / Les antiparkinsoniens au cours du traitement neuroleptique: étude comparative des modes de sevrage progressif et brutal.

The systematic and long term association of anti-parkinsonian drugs to neuroleptics is questioned by many authors because of their side effects and their toxicomanogenous risks whereas their efficiency in extrapyramidal effects of prophylaxis is not certain. This work aims at evaluating the interest of prescribing long term parkinsonian drug in association with neuroleptics. The study centered on 101 psychotic patients treated with neuroleptics, and followed on an ambulatory bases. 97% of this patients systematically received antiparkinsonian drugs. Extrapyramidal symptoms of varied intensity have noted for 61% of patients. The authors have compared, in double blind, the effects of the progressive and abrupt withdrawal of anti-parkinsonian drugs for 37 patients among the 101. These patients have been regularly treated for at least 6 months by neuroleptics (fluphenazine or pipothiazine) in association with trihexyphenidyle. They were randomly divided into 3 groups, and statified by sex and type of neuroleptic. For group I, composed of 13 patients, trihexyphenidyle is abruptly withdrawn and replaced by a placebo. For group II, composed of 11 patients, withdrawal is progressive for 2 weeks, trihexyphenidyle being replaced by a placebo. Group III, composed of 13 patients, is a sample group which went on receiving trihexyphenidyle. The results of this study showed that within the brutal withdrawal group (group I), 10 patients over 13 needed trihexyphenidyle again, whereas only 3 patients over 11 needed it in the progressive withdrawal group (group II). In the sample group (group III), one patient over 13 showed extrapyramidal symptoms, necessitating his leaving school. The global chi 2 is significant with p < 0.001.(ABSTRACT TRUNCATED AT 250 WORDS)

[Prolactin, depression and antidepressive agents. Review of the literature]. / Prolactine, dépressions et antidépresseurs. Revue de la littérature.

Different neurotransmitters (Dopamine, serotonin, GABA...) and hormones (TRH, oestrogenes...) are involved in the central regulation of prolactin synthesis and release. Under physiological conditions, prolactin levels are related to correlate with age, sex, sexual maturational changes (puberty, menopause...), menstrual cycling... In this review of literature there exists a great amount of data concerned with changes in prolactin in affective disorders illustrating the validity of the biochemical and neuroendocrinological approach specially in depression. Different research paradigms are presently reviewed: measurement of plasma levels of prolactin under basal conditions, in a circadian pattern or after pharmacological challenge with TRH and/or morphine (stimulation), L-dopa and/or dexamethasone (inhibition) and its response to antidepressant drugs. The authors emphasize the contradictory results reported in the literature and suggest the need for extreme caution before considering the validity of prolactin as a biochemical test in depression.

[Sleep deprivation and dexamethasone suppression test in healthy volunteers]. / Privation de sommeil et test de freination à la dexaméthasone chez des volontaires sains.

One night sleep deprivation in 10 healthy volunteers was performed: none of them presented an abnormal dexamethasone suppression test (DST) during the following afternoon. In this experimentation, a short deprivation of sleep does not alter DST. Etiopathogenic hypothesis of DST abnormalities (and other factors) have been discussed.